Compare UDMY & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UDMY | DRUG |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Pharmaceuticals and Biotechnology |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 856.4M |
| IPO Year | 2021 | 2020 |
| Metric | UDMY | DRUG |
|---|---|---|
| Price | $4.71 | $86.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | $9.00 | ★ $114.00 |
| AVG Volume (30 Days) | ★ 2.1M | 88.2K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 105.36 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $789,844,000.00 | N/A |
| Revenue This Year | $4.44 | N/A |
| Revenue Next Year | $6.02 | N/A |
| P/E Ratio | $155.00 | ★ N/A |
| Revenue Growth | ★ 0.42 | N/A |
| 52 Week Low | $4.35 | $23.18 |
| 52 Week High | $10.26 | $123.75 |
| Indicator | UDMY | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 44.86 | 55.52 |
| Support Level | $4.35 | $72.06 |
| Resistance Level | $5.06 | $97.75 |
| Average True Range (ATR) | 0.27 | 5.56 |
| MACD | 0.03 | 1.05 |
| Stochastic Oscillator | 59.57 | 85.48 |
Udemy Inc operates a marketplace platform at the center of a vibrant knowledge network. The company operates under two operating and reportable segments Consumer and Enterprise, out of which the Enterprise segment derives the maximum revenue. Geographically, the company derives maximum revenue from North America. The company leverages data, technology, and insights for effective learning experiences. It helps individuals and organizations to possess effective skill acquisition and development with flexibility.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.